Through continuous research and innovation, we manufacture specialty formulations, Zeal Life Sciences aims to provide affordable and quality health care around the world.

Zeal Life Sciences is a pharmaceutical firm dedicated to improving the health and prosperity of countries and rising markets around the world by developing and manufacturing innovative products.

We specifically assist economies with the resources and technology they need to generate and market their own speciality generic molecule and biotechnology treatments. This is accomplished by developing and managing a global portfolio of pharmaceutical products, as well as empowering local production facilities in key areas.

Traditionally, developing countries have imported speciality and innovative pharmaceutical formulations, from outside producers in restricted supply and at a high cost, to the detriment of local individuals and the economy. We want to give a better model for markets that are willing to invest in their own growth.

We aren’t just a pharmacy that sells drugs. Rather, we bring together parties from three groups – medical, science and technology, and business – who share a commitment to the developing world’s prosperity.

Zeal Life Sciences is building a product portfolio comprising the most superior generic medications for intensive and critical therapy and other specialties. We’re also building manufacturing capabilities for these generics, allowing people who can’t always get or afford pricey imported pharmaceuticals to get them.

A generic drug is a knockoff of a brand-name medication. A name-brand drug’s initial patent is usually held by the drug’s inventor. When the patent expires, competing manufacturers may be able to sell generic copies for a much-reduced price. Here are some facts to consider:

Generic medications are just as effective as their brand-name counterparts.

Generics contain the same active ingredients, dosage, effects, side effects, risks, safety, strength, and route of administration as brand-name drugs.

Generics must go through the same clinical trials as brand-name pharmaceuticals and must be approved by the same regulatory organizations.

Generics are substantially less expensive since their producers are not responsible for the high expenditures of developing and marketing a brand-name medicine.

Payers, patients, hospitals, and governments all around the world are seeking health care that is not just of high quality, but also cost-effective. Generic medications are particularly appealing in emerging markets, where rapidly rising patient populations necessitate extended treatment.